tiprankstipranks
Trending News
More News >
Epigenomics (DE:ECX)
FRANKFURT:ECX
Germany Market

Epigenomics (ECX) Income Statement

Compare
1 Followers

Epigenomics Income Statement

Last quarter (Q3 2022), Epigenomics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Epigenomics's net income was $-1.56M. See Epigenomics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ 6.07M$ 697.00K$ 871.00K$ 1.07M$ 1.64M
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 249.00K$ 281.00K$ 246.00K$ 87.00K$ 81.00K
EBITDA
$ -1.94M$ -11.07M$ -13.99M$ -12.57M$ -9.93M
Operating Income
$ -4.16M$ -10.11M$ -15.10M$ -13.29M$ -9.86M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -2.43M$ -11.69M$ -17.02M$ -12.69M$ -10.23M
Per Share Metrics
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Epigenomics Earnings and Revenue History